Gevorg Yaghjyan/LinkedIn
Apr 2, 2026, 15:52
Gevorg Yaghjyan: How Yale is Redefining Bladder Cancer Treatment Through Strategy Focused Trials
Gevorg Yaghjyan, Former Project Leader at Parexel, shared a post on LinkedIn:
“Clinical trials are evolving from testing drugs to testing strategies.
A new study from Yale School of Medicine in metastatic bladder cancer highlights this shift:
- Systemic therapy (ADC plus immunotherapy)
- Response-based patient selection
- Consolidative surgery in responders
This is not a traditional trial.
It’s a multimodal, adaptive treatment pathway.
From a clinical development perspective, key takeaways:
- Dynamic, response – driven enrollment
- Integration of medical plus surgical oncology
- Increasing operational complexity at site level
- Movement toward strategy – based endpoints
This is where oncology trials are heading:
From molecule-focused – to patient pathway – focused design”
Stay updated with Hemostasis Today.
-
Oct 8, 2026, 04:28Jeff Molter: Electrophysiological PIEZO1 Analysis Advances Diagnosis in Hereditary Xerocytosis
-
Oct 8, 2026, 04:23Barbara Adams Krolak: Women and Blood Clots Are We Missing the Warning Signs
-
Oct 8, 2026, 04:10Rutendo Muzambi: Hospital Admission Patterns and Care Disparities in Sickle Cell Disease
-
Oct 8, 2026, 03:50Olfat Berro: Redefining the Future of Haemophilia A
-
Oct 8, 2026, 03:35Tasnia Tarana: Heavy Menstrual Bleeding When the Cause Is Not in the Uterus
-
Oct 8, 2026, 03:28Kian Haseli: Electrophysiological PIEZO1 Analysis Advances Diagnosis in Hereditary Xerocytosis
-
Oct 8, 2026, 03:20Sthanu Subramanian: Leukopenia in Sepsis A Marker of Severe Disease
-
Oct 7, 2026, 16:44Amor Salah: 2026 NCS/SCCM Guidelines for Managing Antithrombotic-Associated ICH
-
Oct 7, 2026, 16:04NETs in Thrombosis: From Mechanism to Therapeutic Target